This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Fresenius Kabi Deutschland Gmbh. Active years: 2013.
Company Filing History:
Years Active: 2013
Title: Manfred Nimtz: Innovator in Polypeptide Conjugates
Introduction
Manfred Nimtz is a notable inventor based in Wolfenbüttel, Germany. He has made significant contributions to the field of biochemistry, particularly in the development of innovative polypeptide conjugates. His work has implications for various medical applications, showcasing the intersection of science and technology.
Latest Patents
Nimtz holds a patent for "Hasylated polypeptides," which relates to hydroxyalkylstarch (HAS)-polypeptide conjugates. This invention comprises one or more HAS molecules, where each HAS is conjugated to the polypeptide via a carbohydrate moiety or a thioether. A preferred embodiment of this invention involves the polypeptide erythropoietin (EPO). This patent highlights his expertise in creating advanced bioconjugates that can enhance therapeutic efficacy.
Career Highlights
Manfred Nimtz is associated with Fresenius Kabi Deutschland GmbH, a company known for its focus on healthcare and pharmaceutical products. His role at the company allows him to apply his innovative ideas in a practical setting, contributing to the development of new medical solutions. His work has been instrumental in advancing the field of biopharmaceuticals.
Collaborations
Nimtz has collaborated with notable colleagues such as Harald Conradt and Eckart Grabenhorst. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise, further enhancing the impact of their collective work.
Conclusion
Manfred Nimtz's contributions to the field of polypeptide conjugates exemplify the importance of innovation in biochemistry. His patent on Hasylated polypeptides represents a significant advancement in medical science, showcasing his dedication to improving healthcare solutions.